Latest Nasdaq News

Elevra Lithium delivered a strong March 2026 quarter with record revenues, operational improvements at North American Lithium, and progress on multiple growth fronts, supported by a robust cash position.

Nova Minerals has secured ASIC registration of its Scheme Booklet for re-domiciling to the US, alongside amendments to warrant terms that triple warrant exchange ratios ahead of the move.

Jindalee Lithium is set to list its McDermitt lithium project on NASDAQ through a US SPAC deal valuing the assets at US$571 million, while securing key US federal approvals and advancing magnesium by-product potential.

Aurora Energy Metals has completed the sale of its Aurora Uranium Project to Eagle Nuclear Energy, receiving US$17.1 million in equity and holding rights to up to US$10 million in milestone payments plus a 1% royalty. The transaction strengthens Aurora's balance sheet and ushers in a new leadership phase.

Critical Metals Corp has consolidated its stake in the Tanbreez Rare Earths Project, gaining government approval to increase ownership to 92.5%, while European Lithium retains a 7.5% interest. This clearance removes a key hurdle, enabling the project’s development to accelerate.

Radiopharm Theranostics has reported encouraging initial results from the Phase 1 HEAT trial of its novel HER2-targeted radiopharmaceutical, 177Lu-RAD202, highlighting tumor uptake and a clean safety profile at the lowest dose with dose escalation approved.

Immuron Limited’s unaudited Q3 FY26 sales rose 16% to AUD 1.5 million, driven by Travelan’s expanding footprint in Australia, Canada, and the US despite a stronger Australian dollar.

Resolution Minerals has appointed seasoned mining executive Brett Lynch as a non-executive director to bolster its U.S. growth strategy ahead of a NASDAQ listing. Lynch’s proven North American critical minerals expertise aligns with the company’s ambitions at its Horse Heaven project in Idaho.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.

Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.